miRNA-Based Therapeutics for Heart Failure: Why Not?

J Am Coll Cardiol. 2020 Apr 21;75(15):1801-1803. doi: 10.1016/j.jacc.2020.03.003.

Authors

Jean-Sébastien Hulot¹, Nihar Masurkar²

Affiliations

¹ Université de Paris, PARCC, INSERM, Paris, France; CIC1418 and DMU CARTE, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France. Electronic address: jean-sebastien.hulot@aphp.fr.
² Université de Paris, PARCC, INSERM, Paris, France.

PMID: 32299592
DOI: 10.1016/j.jacc.2020.03.003

No abstract available

Keywords: animal; heart failure; microRNAs; models, pharmacology; preclinical.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Cardiomyopathies*
Heart Failure*
Ischemia
MicroRNAs*
Reperfusion Injury*
Swine

Substances

MicroRNAs